Experiences with rotavirus vaccines: can we improve rotavirus vaccine impact in developing countries?

A.D. Steele\textsuperscript{a}, J.C. Victor\textsuperscript{b}, M.E. Carey\textsuperscript{c}, J.E. Tate\textsuperscript{c}, D.E. Atherly\textsuperscript{b}, C. Pecenka\textsuperscript{b}, Z. Diaz\textsuperscript{b}, U.D. Parashar\textsuperscript{a}, and C.D. Kirkwood\textsuperscript{b}

\textsuperscript{a}Enteric and Diarrheal Diseases, Bill & Melinda Gates Foundation, Seattle, WA, USA; \textsuperscript{b}Policy, Access and Innovation, Center for Vaccine Innovation and Access, Seattle, WA, USA; \textsuperscript{c}Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA

\textbf{ABSTRACT}

Rotavirus vaccines have been introduced into over 95 countries globally and demonstrate substantial impact in reducing diarrheal mortality and diarrheal hospitalizations in young children. The vaccines are also considered by WHO as “very cost effective” interventions for young children, particularly in countries with high diarrheal disease burden. Yet the full potential impact of rotavirus immunization is yet to be realized. Large countries with big birth cohorts and where disease burden is high in Africa and Asia have not yet implemented rotavirus vaccines at all or at scale. Significant advances have been made demonstrating the impact of the vaccines in low- and lower-middle income countries, yet the modest effectiveness of the vaccines in these settings is challenging. Current research highlights these challenges and considers alternative strategies to overcome them, including alternative immunization schedules and host factors that may inform us of new opportunities.

\section*{Introduction}

There have been significant reductions in global all-cause mortality in young children under five years of age (Under 5) over the last three decades,\textsuperscript{1} yet a common childhood illness – diarrhea – remains a leading infectious cause of pediatric death in children between 1 month and 5 years of age.\textsuperscript{2} Rotavirus is the leading cause of childhood diarrhea and is associated with significant mortality from severe gastroenteritis and rapid dehydration, with the latest annual rotavirus mortality estimates ranging from \~122,322 to 215,757.\textsuperscript{3–5} Analysis of the differences driving these different ranges by the three groups (i.e. Global Burden of Disease (GBD) at the Institute of Health Metrics and Evaluation, University of Washington; Maternal and Child Epidemiology Estimation (MCEE) of the World Health Organization (WHO); and the WHO and US Centers for Disease Control and Prevention (CDC) estimates), has helped our understanding of what these drivers are and offers a transparent platform on which to build future estimates.\textsuperscript{6} Nevertheless, the highest rates of rotavirus mortality and hospitalization are seen in low-income countries (LIC), particularly in sub-Saharan Africa and South Asia, and five countries account for \~50\% of all rotavirus deaths (India, Nigeria, Pakistan, Democratic Republic of Congo and Angola).\textsuperscript{4}

A global analysis of the public health impact of rotavirus vaccines indicated that vaccination in the 72 Gavi-eligible countries would prevent 2.4 million childhood deaths and avert 83 million disability-adjusted life years (DALYs) between 2011 and 2030.\textsuperscript{6} More than 95\% of the averted burden was determined to be in the African, Eastern Mediterranean and South Asian regions. Furthermore, immunization was considered a “very cost effective” intervention for the entire Gavi birth cohort at $42/DALY averted, although differences were noted in different regions. That finding was based upon the then commonly used international definitions for a “very cost effective” intervention (i.e. when the cost per DALY averted is less than the GDP per capita of that country) to demonstrate that rotavirus vaccine was a very cost-effective intervention for every region.\textsuperscript{7} Recent analysis has encouraged countries to utilize these cost-effective ratios within country-specific context and data to inform processes for decision-making.\textsuperscript{8}

Two more recent modeled estimates of the potential impact of rotavirus vaccine in Africa\textsuperscript{9} and Asia,\textsuperscript{10} used current data on regional rotavirus mortality, vaccine effectiveness in introducing countries and observed vaccine coverage. In the 29 African countries that had introduced rotavirus vaccine, an estimated 21,000 deaths and 135,000 hospitalizations were prevented in 2016.\textsuperscript{9} However, if all African countries, including the Democratic Republic of Congo (DRC) and Nigeria had introduced vaccine by December 2014, then an additional 139,000 rotavirus hospitalizations and approximately 27,000 deaths would also have been prevented in 2016. Similar potential incremental impact was estimated for countries in the Asian region where rotavirus vaccines could have prevented over 700,000 hospitalizations and 35,000 deaths due to rotavirus in 2016, if the vaccine had been introduced in all countries before the end of 2014.\textsuperscript{10} Notably, India and...
Pakistan have introduced rotavirus vaccines in a phased manner nationally and Bangladesh is yet to introduce, although it has been approved for support by Gavi.

Two internationally licensed and globally available rotavirus vaccines have been pre-qualified by the World Health Organization (WHO), are licensed in >100 countries, and are being introduced into the routine Expanded Program for Immunization (EPI) schedules of countries. Rotarix™ (GSK Biologicals, Rixensart) is a monovalent (G1P8) human rotavirus strain, which has demonstrated high efficacy and acceptable safety in clinical trials in Europe, Latin America, high-income countries in Asia and Africa using a novel 2-dose schedule for infants.11–14 RotaTeq™ (Merck & Co., Whitehouse, Pennsylvania) is a pentavalent bovine-human reassortant rotavirus vaccine, carrying neutralization epitopes against the common human rotavirus genotypes (G1–G4 and P8 ﹟). It has also demonstrated high efficacy and acceptable safety in clinical trials in the US, Europe, Africa and Asia using the traditional 3-dose EPI schedule for infants.15–17 Based on the high burden of disease in developing countries and on the efficacy of the vaccines to confer protection against moderate to severe rotavirus diarrhea, in 2009 WHO recommended the introduction of rotavirus vaccines in all countries and particularly in countries with high diarrheal disease mortality.18 A third rotavirus vaccine, ROTAVAC™ (Bharat Biotech, Hyderabad, India) obtained WHO prequalification in January 2018, based on a safety and efficacy trial conducted in India.19 India commenced rotavirus vaccine introduction in a phased national introduction in 9 states commencing in 2016, where rotavirus vaccine has been provided as part of the routine immunization program. A second locally produced and licensed rotavirus vaccine (RotaSIIL, Serum Institute of India, Pune) was introduced into a 10th state in early 2018. RotaSIIL was WHO prequalified in September 2018.

Progress with rotavirus vaccines

Global introduction of rotavirus vaccination programs and demonstration of their impact have been among the most rapid in history. Currently, 95 countries have introduced rotavirus vaccine into their national childhood immunization programs, including 45 Gavi-eligible countries which utilized financing support from the Gavi Alliance for vaccine procurement (Figure 1). An additional five countries (Canada, Sweden, Italy, Philippines and Thailand) have used the vaccines regionally. Reassuringly, rotavirus disease and hospitalizations have been consistently reduced in countries that have introduced the vaccines in both high-income (HIC) and upper middle-income countries (UMIC).20–22 Furthermore, country analyses have shown real reductions in diarrhea-related mortality over time, such as in Mexico (35%) and Brazil (22%) after rotavirus vaccine introduction,23,24 demonstrating the powerful impact of rotavirus immunization.

However, the 45 Gavi supported introductions constitute only ~35% of the Gavi birth cohort, and while uptake in sub-Saharan Africa has been widespread, there has been a notable lack of implementation in countries with the highest burden in South Asia, (e.g. Afghanistan only introduced in 2017, India and Pakistan have introduced in a phased approach, and Bangladesh which is yet to introduce despite approval for support by Gavi). Furthermore, in countries with the highest rates of rotavirus-associated mortality in Africa – such as Nigeria and Democratic Republic of Congo (DRC), rotavirus vaccine implementation has not occurred.

In 2016, India introduced their indigenously developed and manufactured rotavirus vaccine, ROTAVAC™, into four early-adopter states to assess the programmatic feasibility of adding a new oral vaccine to their Universal Immunization Program (UIP). In 2017 and 2018, additional states have been included and nation-wide roll out is anticipated in 2019 which will include a second Indian-licensed rotavirus vaccine from Serum Institute. Similarly, several other countries with large birth cohorts such as China, Indonesia and Vietnam also have their own domestic rotavirus vaccine development programs and have not yet introduced vaccine nationally.26

There are several reasons why countries may not have adopted rotavirus immunization. These reasons are multifactorial but include the modest efficacy of the vaccines (45–65% in countries with high Under 5 childhood mortality);27 vaccine pricing and financing concerns; programmatic readiness (e.g. insufficient cold-chain capacity, etc); the lack of a country-specific cost effectiveness data, and global supply considerations. To achieve the full potential global impact that could be expected from rotavirus vaccines, we need to consider each of these issues.

Figure 1. Global introduction of rotavirus vaccines. http://view-hub.org/viz/#
Challenges with the globally available rotavirus vaccines

Twelve years after the first introductions of rotavirus vaccines in 2006, questions remain including: the effectiveness of these live, attenuated oral vaccines in impoverished populations with little access to medical care and high disease co-morbidities including low income and lower-middle income countries (LIC; LMIC), and impoverished communities in some relatively wealthy countries; the duration of protection beyond the first year of life; the possibility of indirect benefits through herd protection of unvaccinated children in high burden settings; and the cross protection against the dynamically evolving variety of rotavirus strains (particularly for the human monovalent vaccine). Two additional questions relating to the young infant have also been raised: the role of potential interference of maternal antibody either transplacentally acquired or via breastfeeding on the effectiveness of the vaccines; and whether environmental enteropathy of the infant gut restricts the live vaccine responses. Specific studies have been conducted over the past 3–5 years to directly address each of these questions.

Vaccine effectiveness in lower-middle and low-income settings

Despite modest clinical efficacy observed in randomized, controlled trials in developing countries in Africa and Asia, ranging from approximately 45–65%, 14,16,17,28 recent studies have documented the real-world impact of the vaccines once introduced into the routine immunization schedule of LICs and LMICs (Table 1). 29 For instance, several Gavi-eligible countries in Latin America including Bolivia, Honduras and Nicaragua demonstrated reductions in diarrhea-related mortality after rotavirus vaccine introduction, compared to no overall reductions in countries that did not introduce the vaccine (Argentina, Chile, Costa Rica, Paraguay). 30 These declining trends in diarrhea mortality post rotavirus vaccine introduction, were notable in infants (<12 months of age) ranging from 30–48% in Nicaragua and El Salvador respectively; and were also observed in children <5 years of age (36–50%) in Nicaragua and El Salvador in the 4-year period post rotavirus vaccine introduction. 30

Moreover, dramatic reductions in rotavirus-associated hospitalizations and in all-cause diarrheal hospitalizations have been documented in several LMICs in Latin America, central Europe and Africa. 31–38 The first LICs to document the effectiveness of rotavirus vaccines have also demonstrated the successful public health impact of the vaccines. For instance, in Malawi, which introduced the monovalent Rotarix™ vaccine in 2012, rotavirus-related hospital admissions decreased by >40%. 37 Rwanda introduced the pentavalent RotaTeq™ vaccine in 2012, showing similar reductions for acute diarrhea hospital admissions (48–49%) and rotavirus-specific admissions (61–70%). 38 These observations of the significant impact of rotavirus vaccines should encourage countries with high diarrheal burden to introduce the vaccines as a priority.

Finally, the cost effectiveness of the vaccines has been favorably evaluated in numerous settings including LIC and LMIC countries. 39,40 In Bolivia for instance, a cost effectiveness analysis was performed to support country decision making in 2017, when it is likely that vaccine subsidy support may be reconsidered. Rotavirus vaccine was demonstrated to be cost effective in Bolivia at their current price in 2011 (US$9/dose) and cost saving at US$3.81 per dose. 41 It was noted that rotavirus vaccination at the the then current price of US$9 per dose was comparatively more cost-effective than most other early childhood interventions including expansion of oral rehydration therapy or vitamin A supplementation. 41

In several African countries, cost effectiveness analyses have also demonstrated the benefit of rotavirus vaccination at both the State and the family level. Ngabo et al. 42 calculated the economic burden of a hospital admission for diarrhea in Rwanda to be US$101, of which direct medical costs were US$44.22 (±US$23.74), and approximately two-thirds of costs (65%) was borne by the household. For the lowest income group, these costs exceeded the household’s monthly income. Several other analyses demonstrated that this is not unique to Rwanda. 43,44 The cost per disability-adjusted life year (DALY) was documented to be very cost effective (defined as costing less than the Gross Domestic Product (GDP) per DALY averted) or cost effective (<3x the GDP per DALY averted) in several countries in Africa including Senegal, Kenya, Uganda, Malawi and Ghana. 43–46 In Ghana, a recent analysis documented that rotavirus immunization will remain very cost effective for the country even after Gavi support ends. 46 In addition, several recent analyses in Asia have documented that rotavirus vaccination would be highly cost effective in Afghanistan, Bangladesh, Laos and Pakistan. 47–50 In Afghanistan, a high mortality setting, rotavirus immunization with or without Gavi support is very cost effective, representing <3% of the country’s immunization budget. Furthermore, the costs per DALY averted are approximately $30/DALY averted when utilizing the Gavi subsidy. 47 In Bangladesh, representing a low diarrhea mortality setting, rotavirus vaccines were also cost effective with or without Gavi subsidy support. 48 Finally, Rheingans and colleagues report that the benefits and cost effectiveness of a rotavirus vaccine program in Pakistan, can be maximized by reaching the highest risk population groups. 50

Table 1. Vaccine effectiveness against hospitalization or hospitalization and emergency department attendance rotavirus gastroenteritis in low income and low-middle income settings.

| Country     | Vaccine outcome | <12mo VE (95% CI) | >12mo VE (95% CI) |
|-------------|----------------|------------------|------------------|
| Armenia     | Rix hospital   | 68 (24.86)       | 60 (20.80)       |
| Bolivia     | Rix hospital   | 64 (34.80)       | 72 (52.86)       |
| Botswana     | Rix hospital   | 57 (50.89)       | 47 (70.70)       |
| Brazil      | Rix hospital, ER | 81 (47.93) | 5 (187.69)     |
| Brazil      | Rix hospital   | 56 (12.78)       | 67 (8.89)        |
| Brazil      | Rix hospital   | 74 (58.84)       | 78 (54.90)       |
| Colombia    | Rix hospital   | 84 (23.97)       | –79 (−559.51)    |
| El Salvador | Rix hospital   | 83 (68.91)       | 59 (27.77)       |
| Ghana       | Rix hospital   | 78 (2.95)        | 50 (−57.84)      |
| Guatemala   | Rix hospital, ER | 78 (18.92) | 71 (44.85)      |
| Malawi      | Rix hospital   | 71 (34.87)       | 32 (−141.81)     |
| Malawi      | Rix hospital   | 62 (29.80)       | 31 (−139.80)     |
| Moldova     | Rix hospital   | 84 (67.92)       | 46 (−16.75)      |
| South Africa| Rix hospital   | 54 (32.68)       | 61 (35.77)       |
| Tanzania    | Rix hospital   | 56 (−2.81)       | 57 (30.86)       |
| Burkino Faso| Teq hospital   | 58 (10.81)       | 19 (−78.63)      |
| Guatemala   | Teq hospital, ER | 74 (18.92) | 71 (44.85)      |
| Nicaragua   | Teq hospital, ER | 78 (49.91) | 55 (22.74)      |
| Nicaragua   | Teq hospital   | 64 (43.78)       | 30 (−5.53)       |
| Nicaragua   | Teq hospital, OP | 65 (80.93) | 81 (25.95)       |

Footnote: adapted from reference 30
**Duration of protection beyond the first year of life**

Several lines of evidence suggest that vaccine-acquired protection is possibly not as enduring or complete as initially predicted. In the African clinical studies, for instance, vaccine efficacy was lower in the second year of life in all settings.\(^{16,51,52}\) Although this was not observed in two Asian studies.\(^{17,53}\) Recent post-hoc analyses of the placebo groups in vaccine trials conducted in Africa, Asia and Europe may shed some light on these observations. Early exposure to wildtype rotavirus infection was demonstrated in a review of the placebo groups within clinical studies, indicating that approximately 25% of infants in Malawi and South Africa had been exposed to natural infection by 20–24 weeks of age.\(^{54}\) This was similar in India although Bangladeshi infants showed the highest rates of early exposure by 20 weeks of age (35%). However, at approximately 6–8 weeks of age, the Asian infants had higher rates of exposure (18–25%) compared to African infants (11–13%), Latin American infants (2–5%) and European infants (0–2%),\(^{54}\) shown in Table 2. A separate post-hoc analysis on the incidence of rotavirus gastroenteritis episodes in various settings, showed that the incidence of any and severe rotavirus gastroenteritis (defined by the Vesikari severity score of ≥11)\(^{55}\) was higher in African infants in the first year of life, than European or HIC Asian infants.\(^{55}\) In addition, the first severe rotavirus episode seemed to occur at a younger age in African children. An earlier review demonstrated that >80% of the rotavirus symptomatic disease occurred in African infants before their first birthday.\(^{56}\) During the second year of life, the incidence of any or severe rotavirus gastroenteritis was lower in Africa, suggesting that these infants were protected by repeated natural infection. Conversely, approximately a third of rotavirus disease was observed in the second year of life in Asian infants from impoverished settings,\(^{57}\) despite similar early exposure. A birth cohort study conducted in Vellore, India, indicated that infants were subject to multiple symptomatic rotavirus episodes in the first 2 years of life, even by the same viral strain.\(^{58}\) It is reasonable to think that differences in the force of infection and pre-existing antibody levels, and possibly access to medical care such as oral rehydration, may play a role in these observed differences in exposure and severe infection.

Similarly, in effectiveness studies conducted after introduction, differences were noted in some settings but not in others. For instance, in Nicaragua, protection waned in the second year of life\(^{53,59}\) compared to the US where it did not.\(^{60}\) In Bolivia, a case control study showed that vaccine effectiveness was diminished in children >12 months of age compared to those <12 months of age, although this trend was not observed for very severe rotavirus diarrhea.\(^{61}\) In Guatemala, a case control study using hospital controls, reported no significant difference in effectiveness between infants 6–12 months of age and children >12 months.\(^{52}\)

Several African countries have reported similar observations in the 2–3 years post introduction, supporting higher impact of the vaccine on hospitalizations in the first year of life, and generally the impact was highest against the more severe disease. Interestingly, vaccine effectiveness in South Africa, where Rotarix™ was administered at an alternative schedule of 6 and 14 weeks of age, was demonstrated to have significant impact against rotavirus gastroenteritis and all-cause diarrhea hospital admissions in both the first year of life and persisted through the second year of life,\(^{62}\) and was documented in both HIV-infected and HIV-uninfected infants.\(^{63}\) Thus, these combined observations suggest that the vaccine, administered at a longer interval between doses, was protective against the most severe rotavirus disease in the first two years of life, which is arguably the most significant public health issue. Certainly, increasing evidence in multiple settings demonstrates that the vaccines prevent rotavirus-associated mortality and hospitalizations.\(^{64}\)

Intriguingly, a decrease in vaccine effectiveness was observed during rotavirus outbreaks in 2009 and 2010 in the Northern Territories of Australia. This low vaccine effectiveness was associated with the emergence of rotavirus antigenic variants, providing the first evidence of rotavirus vaccine escape mutants.\(^{65}\) This suggests that there are multiple scenarios related to the duration of protection afforded by rotavirus vaccines, including possible modest protection in infants in high burden settings, or the emergence of vaccine escape strains, which remains to be quantified as a threat.

**Indirect protection in unvaccinated persons**

Early indications of indirect protection of unvaccinated children was observed in the US within two years of vaccine introduction,\(^{67,68}\) where reductions in rotavirus gastroenteritis were observed in children who were ineligible for vaccination due to their age (i.e. greater than 6 months of age), and in a greater proportion of children <5 years than had been initially been vaccinated. Indirect protection of almost 50% was also noted in US adults who were clearly not vaccinated, demonstrating a broader public health impact.\(^{69}\) This indirect protection has been documented in other HIC settings in Australia and Europe,\(^{70–72}\) highlighting the potential added benefit of rotavirus immunization. Furthermore, in South Africa, a vaccine impact study conducted after the introduction of Rotarix™ in 2009, demonstrated reductions in children between 12 and 24 months of age, who were too old to be vaccinated.\(^{73}\)

The remaining question is whether significant indirect protection will be observed in LMICs and LICs where the force of infection is far higher. A cluster randomized trial of Rotarix...
introduction in rural Bangladesh attempted to measure indirect protection but found none.\textsuperscript{74} The authors noted that larger scale sustained vaccination may have been required in such a high force of infection setting to obtain measurable indirect effects. Early data from country introductions in Armenia and Moldova suggest that indirect effects may be observed in some settings in LMICs.\textsuperscript{32,33} It is likely that the level of indirect protection will depend on the intensity of rotavirus transmission in a population, coverage with vaccine, and the level of protection afforded to vaccinees.

**Cross protection of dynamically evolving rotavirus strains**

Rotavirus ‘genotypes’ are defined by gene sequences of the two outer capsid proteins; namely the VP7 glycoprotein outer capsid protein (G-types), and the VP4 protease-sensitive viral receptor which protrudes as a spike from the surface of the particle (P-types). The genotype characteristics of the VP7 (G for glycoprotein) and VP4 (P for protease-sensitive) are identified by reverse transcriptase PCR of portions of the genes encoding these two major external antigens of the viral particle which are considered important neutralization antigens.\textsuperscript{75}

In the pre-vaccine era, rotavirus strains underwent temporal and spatial changes each year within and between countries. In the past two decades, six rotavirus genotypes were identified as the common human virus strains causing disease – G1P[8], G2P[4], G3P[8], G4P[8], G9P[8] and G12P[8].\textsuperscript{75,76} Genotype G1P[8] strains are consistently present and predominate globally, representing ~70% of strains in developed countries, but only 25–50% in countries in South America, Africa and the Indian subcontinent.\textsuperscript{76–78}

Both vaccines have demonstrated effective clinical protection against multiple homotypic or heterotypic rotavirus strains. For the monovalent (G1P[8]) Rotarix™ vaccine, heterotypic cross protection was a specific concern, but the vaccine was protective against completely heterologous strains – G2P[4], G8P[6] and G12P[6] in developing countries.\textsuperscript{79,80} Similarly, the pentavalent RotaTeq™ vaccine (G1–G4 and P[8]) has shown protection against non-vaccine strains.\textsuperscript{15,81} Nevertheless, there has been much conjecture whether widespread use of rotavirus vaccines would result in evolutionary selective pressure resulting in strain replacement, as was seen after the introduction of pneumococcal vaccine. Early observations of the strains circulating in countries after rotavirus vaccine introduction hint at the potential for strain replacement. Findings in Australia, Belgium, Latin America and the USA have revealed significant changes in the diversity and distribution of the circulating wildtype rotavirus population following vaccine introduction with both Rotarix™ or RotaTeq™.\textsuperscript{82}

For example, in the post-vaccine era genotype G2P[4] strains emerged as a common cause of disease in several settings, and circulated in a prolonged manner over several years,\textsuperscript{83} compared to earlier observations that G2P[4] strains tended to occur in a cyclic manner every 2–3 years. Similarly, G3P[8] strains emerged as a more common genotype in the post-vaccine era, in contrast to its relatively minor role in the pre-vaccine era.\textsuperscript{84,85} Furthermore, genotyping data post vaccine introduction revealed the identification of previously unrecognized genotype recombinants, such as G3P[14].\textsuperscript{86,87} A recent detailed phylogenetic analysis of the full genome analysis of G1P[8] strains from Belgium and Australia post-introduction showed evidence of specific, distinct viral sub-clusters present before and after vaccine introduction. Interestingly, the emergence of unique viral clusters identified only after vaccine introduction may be the first sign of vaccine-induced evolutionary pressure.\textsuperscript{88}

Thus, molecular epidemiological and bioinformatics studies indicate that rotavirus genotypes appear to be more diverse and dynamic following vaccine introduction. The shift in strain diversity may be due to natural annual fluctuations of the circulating strains which has been widely documented,\textsuperscript{75–78} although the distinct distribution patterns and divergent strains emerging in the vaccine era appear unique and suggest that mass vaccination has had an impact on circulating genotype diversity.

However, this complex question requires careful consideration of three important issues for the global public health impact of rotavirus vaccination. First, rotavirus vaccination prevents disease, but does not result in sterilising immunity and thus subsequent reinfection occurs. This is similar to the natural history of the disease where children are infected multiple times during the first few years of life, but most of these subsequent infections are subclinical and non-life threatening. While it is true that vaccination may generate an immune environment that will exert novel immunological pressures on the circulating genotype diversity of the disease, it is likely that the level of indirect protection will depend on the intensity of rotavirus transmission in a population, coverage with vaccine, and the level of protection afforded to vaccinees.
may not occur, but requires continued monitoring to ensure that we see the continued impact of the current or new rotavirus vaccines.

**Vaccine interference by maternal antibody**

Several studies have evaluated the role of maternal antibody, whether transplacentally-acquired or via breastfeeding, on the response to rotavirus vaccines. Initial reports of the impact of maternal antibody on the replication of live attenuated rotavirus vaccines in *in vitro* fueled a flurry of studies evaluating this specific question. First, several studies have shown that maternal IgG titres of anti-rotavirus antibody is important early in life and is reflected in passively acquired infant IgG titres. This transplacentally-acquired antibody protects the very young infant; and the maternal serum IgG titres are negatively correlated with the immune response of the infant to the vaccines. High levels of pre-existing serum IgG in the infant, including maternally derived IgG, have an inhibitory effect on the immunogenicity of both the monovalent human rotavirus vaccine, and the pentavalent reassortant vaccine.

In addition, several studies have explored the role of maternal antibody acquired through breastfeeding – both as an active inhibitor of viral replication at the time of administration of the oral, live vaccine, and assessing the impact of high titres of anti-rotavirus breastmilk antibody on vaccine take. Anti-rotavirus IgA and IgG are generally higher in women in impoverished settings, presumably due to constant exposure to wildtype rotavirus and have been recorded to negatively impact the replication of the vaccine in the infant gut. However, studies assessing the effect of withholding breastfeeding before and after actual vaccine administration did not show a negative impact of the concomitant breastfeeding, and in fact one study showed slightly better IgA immune responses in those infants fed at the time of administration. Thus, although breastmilk antibody titres might be higher in some populations and this may have some effect on the first rotavirus vaccine dose, the available data indicates that after the full course of vaccines, this effect appears nullified. The overall benefits of breastfeeding, particularly in young infants in developing countries, far outweigh the limited interference of breastmilk antibody on rotavirus vaccine take. Furthermore, WHO recommends exclusive breastfeeding up until 6 months of age – so over the period that infants receive their childhood immunizations – and recommends continued breastfeeding during a diarrheal episode.

**Environmental enteric of the infant gut**

Environmental enteric dysfunction (EED) is a subclinical enteric condition of children in developing countries that is characterized by intestinal inflammation, reduced intestinal absorption and gut barrier dysfunction. A clinical study of Rotarix™ and oral polio vaccine (OPV) conducted in Bangladeshi infants demonstrated that >80% of the children had signs of EED by 12 weeks of age, based on a range of fecal biomarkers for intestinal inflammation. EED was also associated with malnutrition at 12 months of age (28% of infants had HAZ scores of ≤2), and with micronutrient deficiencies, including zinc. Interestingly, EED was associated with failure to respond to OPV or Rotarix™ vaccination (20% and 69%, respectively), although immune responses to the parenteral vaccines were not impaired.

**Rotavirus, histo-blood group antigens and microbiome**

New avenues of research to elucidate the lower efficacy of rotavirus vaccines in developing country infants include an examination of host factors. Recent studies have demonstrated that rotaviruses, like other enteric pathogens, recognize and bind to human histo-blood group antigens (HBGAs) in a strain-dependent manner. For rotaviruses, the HBGAs-binding is mediated by the VP4 outer membrane protein via a glycan-binding site found on the VP8* (a cleavage product of VP4). A recent study exploring these phenomena, examined rotavirus infection in infants from Burkina Faso and Nicaragua, reporting that rotavirus strains with P8 genotypes exclusively infected individuals with Lewis-positive and secretor-positive phenotypes. Conversely, P6 rotavirus strains predominantly infected Lewis-negative individuals, irrespective of the secretor status. These are intriguing findings because (i) this human phenotype (Lewis-negative) is much more common in African populations, and (ii) the rotavirus P6 genotypes circulate at very high levels in Africa, possibly contributing to the lower efficacy of vaccines carrying the VP4. Recently, Lee and colleagues reported that non-secretor status was associated with reduced risk of rotavirus diarrhea in Bangladeshi infants, however, there was no evidence non-secretors were resistant to P8 infection. In this study, reduced VE was mediated by complete protection from P4 infection rather than reduced P8 susceptibility. Further research is needed to understand how significant this issue is.

Harris and colleagues examined the role of the microbiome in responsiveness to the orally administered vaccine. First, vaccine responders in a clinical study in Ghana were matched to non-responders in the same study, using several parameters including age, village, month of vaccination, height and weight. Intriguingly, in this small study, bacteria related to *Streptococcus bovis* were significantly associated with vaccine immune response, and it was speculated that the bacterial family may have acted as an inadvertent adjuvant due to toxigenic lipo-polysaccharide (LPS) and ability to trigger an immune response. In addition, the Ghanaian microbiome in vaccine non-responders demonstrated higher abundance of bacteria belonging to the *Bacteroidetes* phyllum, which includes bacterial species expressing functionally and structurally distinct LPS. This was confirmed in a control group of Dutch infants who were assumed to be high-responders to the vaccine. The signature intestinal microbiota were shared in a small pilot study in Pakistani infants, but not in Indian infants. The results are preliminary but indicate that there may be some answers to the lower “vaccine take” submerged in the microbiome of infants in developing countries.

**Can we improve the performance of live oral rotavirus vaccines?**

Rotavirus vaccines are based on the concept that live, attenuated vaccine strains that are orally delivered will mimic natural infection resulting in viral replication in the gut and the stimulation of mucosal immunity. Although this principle worked well in developed country infants, we know that these live, attenuated oral
vaccines are less effective in developing countries as described above. Several studies have been undertaken to evaluate whether it is possible to enhance the performance of these rotavirus vac-
cines in developing country infants through changing the immu-
nization schedule or giving additional doses and/or micro-
supplementation.

**Immunization schedules with additional doses**

Rotarix™ is marketed as a 2-dose product to be administered at 6
and 10 weeks of age. It was initially believed that three doses of a live,
oral rotavirus vaccine would be required, and given the existing
3-dose EPI schedule for DPT (now pentavalent vaccine
containing DPT-Hib and Hepatitis B vaccine), all rotavirus vac-
cines were evaluated on a 3-dose regimen, including Rotarix™. How-
ever, early studies for the licensure of the Rotarix™ vaccine
conducted in Brazil, Mexico and Venezuela and in Finland
demonstrated that vaccine gave good protection against severe
rotavirus gastroenteritis after 2 doses,10,11 and this schedule
was utilized in the large pivotal licensure studies.11–13

The clinical studies evaluating efficacy and immunogenicity of
Rotarix™ in African infants in Malawi and South Africa, were
designed with a 2-dose schedule (10 and 14 weeks of age) and a
3-dose schedule (6, 10 and 14 weeks of age) as it was unknown
whether the 2-dose schedule would provide sufficient protection
in these settings.14 The IgA seroconversion rates and geometric
mean concentrations (GMCs) were moderately higher in the
3-dose arms, although not statistically significantly so. Vaccine
efficacy was higher in the 3-dose arm of the South African cohort,
although in Malawi, protection in the first year of life was similar
for the two schedules.15 However, in the second year of life,
protection was significantly higher for infants who received three
doses of the vaccine in both countries,51,52 suggesting that a 3-dose
schedule might have greater public health impact. Nevertheless,
the 2-dose schedule was adopted as recommendation policy in
2009 when SAGE reviewed this data, although they did request
additional data on this specific question.16

Thus, to further investigate the potential benefit of providing
three Rotarix™ doses in the primary series, two similarly designed
trials were conducted in Pakistan and Ghana using immunologic
outcomes. IgA is not a mechanistic correlate of protection for
rotavirus but has been routinely used as a surrogate marker to
indicate “vaccine take” in all clinical studies. Anti-rotavirus IgA
was measured among children receiving Rotarix™ at 6, 10 and
14 weeks of age, compared to that among children receiving
vaccine at the recommended 6 and 10 weeks of age, or at the
delayed schedule of 10 and 14 weeks of age. In Pakistan, there was
no difference between the proportion of infants who serocon-
verted (3-dose arm, 36.7% compared to 2-dose arm, 36.1%), nor
the geometric mean concentrations after the full series in the
3-dose arm (25.8 U/ml) compared to the 2-dose arm (24.0 U/
ml).112 In contrast, in Ghana, significantly more infants serocon-
verted in the 3-dose arm compared to the 2-dose arm (43.4%
versus 28.9%, p = 0.014). This improvement in immune response
was also demonstrated by the GMCs which were significant higher
in the 3-dose arm (32.6 U/ml versus 22.1 U/ml, p<0.038).107

It is unclear why a third dose of Rotarix™ administered in the
primary series stimulated higher immune responses in Ghana,
although this is consistent with other studies in African popula-
tions studied.14,51,52,113 An additional dose of rotavirus vaccine in
the primary series may simply provide some children another
opportunity to respond to vaccine or could give a modest boost
in immunity after initial presentation from the earlier doses. As
noted above, there are challenges to live oral vaccines in these
infant populations. Given the sub-optimal efficacy that current
rotavirus vaccines offer infants and young children in the devel-
oping world, even a modest improvement in immunity may
translate into substantially more infants protected.

**Booster dose of rotavirus vaccine at 9 months**

Another strategy to help overcome interference from maternal-
derived antibody and waning immunity in the second year of life,
may be the provision of an additional dose of vaccine later in
infancy. Investigators in Bangladesh studied the immunologic
effect of administration of a booster dose of rotavirus vaccine at
9 months of age with measles/rubella vaccines, to infants who had
received two doses of Rotarix™ at 6 and 10 weeks of age.114
Importantly, the immune response to measles vaccine was not
negatively impacted. Serum IgA and IgG to rotavirus were mea-
sured prior to, and two months post the booster dose, demonstrat-
ing enhanced rotavirus antibody titres. Infants with negative
baseline serum IgA or IgG titres (<20 U/ml), developed sero posi-
tive levels ≥20 U/ml after the booster dose, indicating a response to
the vaccine in 43.6% (95% CI, 34.7% to 53.0%) and 68.8% (95% CI,
57.9% to 77.9%) of infants, respectively. No changes in serum
antibody levels were noted among the group of infants not receiv-
ing the booster dose. Most infants demonstrated improvements in
anti-rotavirus serum antibody titres, and this was specifically
observed among the infants with lowest antibody levels pre-
vaccination, and who would likely benefit most, in terms of
improved protection, from receipt of the booster dose.114 Similar
results were observed in Mali.115 A study modelling the booster
dose strategy has shown that a significant number of additional
deaths could be averted if a booster dose re-established VE to the
levels seen in year 1 during the second year of life.116

**Neonatal dosing for rotavirus vaccines**

A novel strategy to avoid interference from maternal antibo-
dies or EED, is to employ a neonatal immunization strategy.
A birth vaccine dose may also enhance the coverage and
timeliness of vaccine completion, particularly in regions with
vaccine programmatic challenges,117 although limited evalua-
tion of rotavirus vaccines has occurred in this period. Most
recently, the asymptomatic neonatal rotavirus vaccine (RV3-
BB) was evaluated in a Phase IIb immunogenicity and efficacy
study employing a birth dose (<5 days of age), as part of a
3-dose regime in a randomized double-blinded placebo-
controlled study in Indonesia.118 Overall, a VE of 63% was
observed for 18 months follow-up, when including the infant
and neonatal participants together. In the neonatal arm, a VE
of 94% was observed at 12 months and 75% at 18 months.
These extremely promising efficacy results show the potential of using a neonatal rotavirus strain that was adapted to the newborn gut. Early rotavirus vaccine candidates, which have been discontinued, were evaluated in Finnish and Ghanaian infants showing good immunogenicity and protection against moderate to severe rotavirus gastroenteritis. Taken together this data suggests that a neonatal administration schedule could be an attractive alternative that could help improve vaccine efficacy and extend protection, particularly given the early exposure to rotavirus infection noted earlier in the placebo groups of trials conducted in developing countries.

**Micro-supplementation with zinc and probiotics**

Zinc is critical to immune function, and research demonstrates that zinc deficiency negatively impacts the immune system. Zinc deficiency is common in low-resource populations in Africa and Asia, and supplementation is proposed as a potential strategy to improve immune responses to vaccinations. Indeed, zinc deficiency was associated with EED and the failure of oral rotavirus vaccine noted above. Several studies have examined the relationship between zinc and immune responses to childhood immunization, but positive results have been few. In two trials of oral inactivated cholera vaccine in Bangladesh, daily zinc supplementation (20 mg of elemental zinc) for six weeks resulted in a significant increase in the proportion of 2–5 year olds and 10–18-month-old children who had a four-fold or greater increase in vibriocidal antibody titer. However, no effect was measured among infants 6–9 months of age.

The intestinal microbiota, as noted earlier, also play a significant role in maturation of gastrointestinal tract health and in mucosal immune function. Lactobacilli are normal commensals of the gut and play a role in regulating the intestinal microbiota and have been regarded as safe and effective probiotics. Studies in gnotobiotic piglets have demonstrated that *Lactobacillus rhamnosus* GG improves the mucosal barrier function in piglets challenged with rotavirus and enhanced the mucosal B-cell responses to rotavirus challenge. Thus, it has been proposed that the use of probiotics might enhance the mucosal immune responses to live, attenuated rotavirus vaccines that replicate in the gut.

In a clinical trial of zinc supplementation, with or without probiotics, on the response to rotavirus vaccine, infants in India received daily supplementation of elemental zinc from their sixth week of life until 11 weeks of age, and half the infants also received supplementation with a probiotic (10⁹ *Lactobacillus rhamnosus* GG). The study was inconclusive but may have been due to lack of sufficient zinc dosing to show an effect. It is clear that additional research is required in this area. Most basic research of zinc effects on immune function have centered on the peripheral immune system; there is currently almost no information about the effect of zinc deficiency or supplementation on mucosal immunity.

**Global supply**

Currently, there are four WHO prequalified vaccines, which are available for Gavi-eligible countries with financial support from UNICEF for vaccine procurement. In recent years, and based on demonstrated country preference for one product, some short-term supply constraints have been seen. As several large countries plan to introduce vaccine in 2018 and 2019, this situation is likely to be exacerbated. Based on an earlier assessment by Gavi, rotavirus vaccine demand by Gavi-eligible countries will increase to 66 million courses per year, and will require the entry of at least one, if not both, additional vaccine manufacturers with prequalified vaccines to meet this demand and that of the non-Gavi-eligible LMIC and UMIC countries. The advent of both Indian pre-qualified vaccines should help this situation, and fortunately, there are several other new vaccine products in development that should offset growing demand for rotavirus vaccine within a few years.

**Conclusions**

Live-attenuated, orally administered rotavirus vaccines have repeatedly demonstrated their value in reducing rotavirus-associated deaths and hospitalizations in all settings evaluated. The benefits of rotavirus immunization, particularly in countries with high diarrhea burden, are quantifiable and cannot be denied. Yet, despite these successes, many countries have not introduced rotavirus vaccines.

Rotavirus vaccines have a unique trajectory in that the vaccines were introduced into the United States and Gavi-eligible countries in the same year. In 2006, Nicaragua introduced vaccine with the support of the Pan American Health Organization (PAHO) and the Revolving Fund. The leadership of Nicaragua has continued with multiple assessments indicating the reduction in diarrheal hospitalizations, the cost effectiveness of the vaccine, and the impact of the human monoclonal vaccine against heterotypic strains. This has paralleled the impact demonstrated in the United States and in other countries in this region over the past 10 years.

Concerns about the modest efficacy of the vaccines in developing countries may have impacted country decision making for vaccine introduction. Several studies over the past 5 years have attempted to understand the role of various host or virus factors that might have played a role in the reduced efficacy observed. In essence, these studies have shown that several factors specific to children in impoverished settings with high exposure do impact the immune response to the vaccines, such as maternal antibody titres, environmental enteric dysfunction, co-administration of oral poliovirus vaccine, etc. Nevertheless, the vaccines still demonstrate good public health impact, and have described additional benefit through indirect herd effects. Furthermore, immune responses can be improved by changes to the number and timing of doses of the vaccine, although enhanced clinical protection has yet to be documented. Effectiveness studies to assess the clinical protection of differing immunization schedules should be considered to enhance the observed benefits. Finally, multiple cost effectiveness studies in various economic settings have demonstrated the clear benefit and cost-effective nature of rotavirus vaccines.

Early questions of the cross-protective benefit of the vaccines, particularly the monovalent (G1P[8]) human rotavirus vaccine have also proven unsubstantiated. It is apparent that
large scale rotavirus immunization may drive natural evolution and diversity of the viral strains post-immunization, but this has not reduced the overall major effect of the vaccines on reducing diseases and virus transmission. Several analyses have also demonstrated the heterotypic cross-protection of both Rotarix and RotaTeq vaccines against multiple strains and completely heterologous strains. We should continue to monitor the strains circulating post-immunization and assess their potential intrusion as vaccine escape mutants with heightened disease burden.

Finally, countries may delay the decision to introduce rotavirus vaccines, which are relatively costly compared to the older generation of childhood vaccines. Cost effectiveness analyses have established that rotavirus vaccines are very cost-effective (<1 x GDP per DALY-verted) or cost effective (<3x GDP per DALY-verted), to the country, using common criteria for cost-effectiveness. In addition, Gavi subsidy for vaccine procurement through UNICEF, means that the country payment is as low as $0.20 per dose. Non-Gavi LMIC countries have to pay more for vaccine. Cost effectiveness analysis is an extremely powerful tool to assist country-decisions to introduce rotavirus vaccines.

Importantly, countries in Africa have also ramped up introduction of rotavirus vaccines from the first introduction in 2009 in South Africa. The continent houses 9 of the 10 countries with the highest rates of rotavirus mortality per 100,000 population. Currently, 36 of 54 countries in the continent have introduced rotavirus vaccines into the Expanded Program for Immunization (EPI), and many have documented the major impact of immunization on rotavirus hospitalizations and deaths. The enormous benefits demonstrated by countries utilizing the vaccines, and the continued support of Gavi and UNICEF for vaccine procurement, will continue to drive vaccine introduction in more countries in the immediate future. This should show even greater impact on reductions in diarrheal mortality over time.

Disclaimer

The finding and conclusions in this report are those of the authors and do not necessarily represent the official position of the Bill & Melinda Gates Foundation, nor PATH. The finding and conclusions in this report are those of the authors and do not necessarily reflect the official position of the US Centers for Disease Control and Prevention.

Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

References

1. You D, Hug L, Ejdemyr S, Idele P, Hogan D, Mathers C, Gerland P, New JR, Alkema L. 2015. Global, regional, and national levels and trends in under-5 mortality between 1990 and 2015, with scenario-based projections to 2030: a systematic analysis by the UN inter-agency group for child mortality estimation. Lancet. 386:2275–2286. doi:10.1016/S0140-6736(15) 00120-8.
2. Walker CL, Aryee MJ, Boschi-Pinto C, Black RE, Myer L. 2012. Estimating diarrheal mortality among young children in low- and middle-income countries. PLoS ONE. 7:e29151. doi:10.1371/journal.pone.0029151.
3. GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390:1151–1210. doi:10.1016/S0140-6736(17)32152-9.
4. Tate JE, Burton AH, Boschi-Pinto C, Parashar UD. Global, regional, and national estimates of rotavirus mortality in children ≤5 years of age, 2000-2013. Clin Infect Dis. 2016;62(S2):S96–105. doi:10.1093/cid/civ1013.
5. Troeger C, Khalil IA, Rao PC, Cao S, Blacker BF, Ahmed T, Armah G, Bines JE, Brewer TG, Colombara DV, et al. The changing epidemiology of rotavirus and its role as the leading cause of diarrhea burden among children under 5 years old. JAMA Pediatr. 2018 Aug 13. doi:10.1001/jamapediatrics.2018.1960.
6. Clark A, Black R, Tate J, Roose A, Kotloff K, Lam D, Blackwelder W, Parashar U, Lanata C, Kang G, et al. Estimating global, regional and national rotavirus deaths in children aged ≤5 years: current approaches, new analyses and proposed improvements. PLoS ONE. 2017;12(9):e0183399.
7. Atherly DE, Lewis KD, Tate J, Parashar UD, Rheingans RD. 2012. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030. Vaccine. 30:A7–14. doi:10.1016/j.vaccine.2011.12.096.
8. Bertram MY, Jaur A, de Joncheere KD, Edejer T, Hutubessy R, Kieny M-P, Hill SR. 2016. Cost effectiveness thresholds: pros and Cons. Bull WHO. 94:925–930. doi:10.2471/BLT.15.164418.
9. Shah MP, Tate JE, Mwenda JM, Steele AD, Parashar UD. Estimating reductions in hospitalizations and deaths from childhood diarrhea following implementation of rotavirus vaccination in Africa. Exp Rev Vaccines. 2017;16(10):987–995. doi:10.1080/14760584.2017.1371595.
10. Burnett E, Tate JE, Kirkwood CD, Nelson EAS, Santoshm M, Steele AD, Parashar UD. Estimated impact of rotavirus vaccine on hospitalizations and deaths from rotavirus diarrhea among children ≤5; in Asia. Exp Rev Vaccines. 2018;17(5):453–460.
11. Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R, Meurice F, Han HH, Damaso S, Boukennooge A. 2007. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomized, double-blind controlled study. Lancet. 370:1757–1763. doi:10.1016/S0140-6736(07)61744-9.
12. Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, Cervantes Y, Linhares AC, López P, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. Human rotavirus vaccine study group. N Engl J Med. 2006;354:11–22.
13. Phua KB, Lim FS, Lau YL, Nelson EAS, Huang LM, Quak SH, Lee BW, van Doorn LJ, Teoh YL, Tang H, et al. 2012. Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: a randomized clinical trial in an Asian population. Vaccine. 30:4552–4557. doi:10.1016/j.vaccine.2012.03.030.
14. Madhi SA, Cunliffe NA, Steele AD, Witte D, Kirsten M, Louw C, Ngwira B, Victor JC, Gillard PH, Cheuvart BB, et al. 2010. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med. 362:289–298. doi:10.1056/NEJMoa0904797.
15. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santoshm M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, et al. 2006. Safety and efficacy of a pentavalent human-bovine (WC3) reasortant rotavirus vaccine. N Engl J Med. 354:23–33. doi:10.1056/NEJMoa052664.
16. Armah GE, Sow S, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, Binka FN, Steele AD, Laserson KF, Ansah NA, et al. 2010. Efficacy of the pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: A randomized, double blind placebo-controlled trial. Lancet. 376:606–614. doi:10.1016/S0140-6736(10)60899-2.
17. Zaman K, Dang DA, Victor JC, Shin S, Yunus M, Dallas MJ, Podder G, Vu DT, Le TPM, Luby SP, et al. 2010. Efficacy of
penta-valent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: A randomized, double-blind, placebo-controlled trial. Lancet. 376:615–623. doi:10.1016/S0140-6736(10)60755-6.

18. WHO. 2009. Rotavirus vaccines: An update. Weekly Epidemiol. Rec. 84:53–56.

19. Bhandari N, Rongsen-Chandola T, Bavdekar A, John J, Antony K, Taneya S, Goyal N, Kawade A, Kang G, Rathore SS, et al. Efficacy of a monovalent human bovine (116E) rotavirus vaccine in India infants: A randomized, double-blind, placebo-controlled trial. Lancet. 2014;383(9935):2136–2143. doi:10.1016/S0140-6736(13)62630-6.

20. de Oliveira LH, Danovaro-Holliday MC, Andrus JK, de Fillipis AMB, Gentsch J, Matus CR, Widdowson M-A. Sentinel hospital surveillance for rotavirus in Latin American and Caribbean countries. J Infect Dis. 2009;200 Suppl 1(Suppl 1):S131–9. doi:10.1086/505060.

21. Tate JE, Panozzo CA, Payne DC, Patel MM, Cortese MM, Fowlkes AL, Parashar UD. 2009. Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. Pediatrics. 124:465–471. doi:10.1542/peds.2008-3528.

22. Karafillakis E, Hassounah S, Atchison C. 2015. Effectiveness and impact of rotavirus vaccines in Europe, 2006–2014. Vaccine. 33:2097–2107. doi:10.1016/j.vaccine.2015.03.016.

23. Richardson V, Parashar U, Patel M. 2011. Childhood diarrhea deaths after rotavirus vaccination in Mexico. N Engl J Med. 365:772–773. doi:10.1056/NEJMcc100062.

24. Do Carmo GM, Corte J, Siqueira AA, de Oliveira WK, Cortez-Escalante JJ, Lopman B, Flannery B, de Oliveira LH, Hage Carmo E, et al. 2011. Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis. PLoS Med. 8:e1001024. doi:10.1371/journal.pmed.1001024.

25. Bhan MK, Glass RI, Khan KM, Bhandari N, Boslego J, Greenberg HB, Mohan K, Cunlin G, Rao TS. 2016. Team science and the creation of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: A cluster randomized trial. PLoS Med. 2014;383(9935):2180–2183. doi:10.1016/S0140-6736(14)60191-4.

26. Kirkwood CD, Steele AD. 2017. Rotavirus vaccine will have an impact in Asia. PLoS Med. 14:e1002298. doi:10.1371/journal.pmed.1002298.

27. WHO. 2013. Rotavirus vaccines position paper January 2013. WER. 88:49–64.

28. Zaman K, Sack DA, Neuzil KM, Page S, Kaur K, Camps C, Heyderman RS, et al. 2015. Effectiveness of rotavirus vaccine introduction and vaccine effectiveness in the Republic of Moldova. Clin Infect Dis. 62:S140–46. doi:10.1093/cid/civ1209.

29. Armah GE, Pringle K, Enweronu-Laryea CC, Ansong D, Mwenda JM, Djamenu SK, Narh C, Cartey B, Binka F, Gytdal S, et al. 2016. Impact and effectiveness of monovalent rotavirus vaccine against severe rotavirus diarrhea in Ghana. Clin Infect Dis. 62:S200–07. doi:10.1093/cid/civ014.

30. Mpalabwani EM, Simwaka CJ, Mwenda JM, Mubanga CP, Monze M, Matopo B, Parashar UD, Tate JE. 2016. Impact of rotavirus vaccination on diarrheal hospitalizations in children aged 8-5 years in Lusaka, Zambia. Clin Infect Dis. 62:S183–87. doi:10.1093/cid/civ1027.

31. Bar-Zeev N, Kandapa L, Tate JE, Jere KC, Iturriza-Gomas M, Nakagomi O, Mwansambo C, Costello A, Parashar UD, Heyderman RS, et al. 2015. Effectiveness of a monovalent rotavirus vaccine in infants in Malawi after programmatic roll-out: an observational and case-control study. Lancet Infect Dis. 15:422–428. doi:10.1016/S1473-3099(14)71060-6.

32. Ngabo F, Tate JE, Gatera M, Rugambwa C, Donnen P, Lepage P, Mwenda JM, Binagwaho A, Parashar UD. 2016. Effect of pentavalent rotavirus vaccine introduction on hospital admissions for diarrhoea and rotavirus in children in Rwanda: a time-series analysis. Lancet Glob Health. 4:e129–36. doi:10.1016/S2214-109X(15)00270-3.

33. Tu HA, Woordenbag HJ, Kane S, Rozenbaum MH, Li SC, Postma MJ. 2011. Cost-effectiveness of rotavirus immunization for developing countries: a review of the literature. Expert Rev Vaccines. 10:1037–1051. doi:10.1586/erv.11.65.

34. Rheingans AR, Amaya M, Anderson JD, Chakraborty P, Atem J. 2014. Systematic review of the economic value of diarrheal vaccines. Hum Vaccin Immunother. 10:1582–1594. doi:10.4161/erv.29352.

35. Smith ER, Rowlinson EE, Iniguez V, Etienne KA, Rivera R, Maman N, Rheingans R, Pati Z, Malker P, Leon JS. 2011. Cost-effectiveness of rotavirus vaccination in Bolivia from the State perspective. Vaccine. 29:6704–6711. doi:10.1016/j.vaccine.2011.05.038.

36. Ngabo F, Mvundura M, Gazley L, Gatera M, Rugambwa C, Kayonga E, Tuyishime Y, Niybaho J, Mwenda JM, Donnen P, et al. 2016. The economic burden attributable to a child’s iMPatient admission for diarrheal disease in Rwanda. PLoS ONE. 11: e0149805. doi:10.1371/journal.pone.0149805.

37. Diop A, Atherly D, Faye A, Lamine Sall F, Clark AD, Ndiaye M, Yade B, Ndiaye M, Fata Cissé M, Ba M. Estimated impact and cost-effectiveness of rotavirus vaccination in Senegal: a country-led analysis. Vaccine. 2015;33(Suppl 1):A119–25. doi:10.1016/j.vaccine.2014.12.065.

38. Sigei C, Odaga J, Mvundura M, Madrid Y, Clark AD. Cost-effectiveness of rotavirus vaccination in Kenya and Uganda. Vaccine. 2015;33(Suppl 1):A109–18. doi:10.1016/j.vaccine.2014.12.079.

39. Bar-Zeev N, Tate JE, Peckenca C, Chikaka JM, Mvula H, Wachepa R, Mwansambo C, Mhango T, Chirwa G, Crampin AC, et al. 2016. Cost-effectiveness of monovalent rotavirus vaccination in Malawi: a post-introduction analysis using individual patient level costing data. Clin Infect Dis. 62:S220–28. doi:10.1093/cid/civ1025.

40. Nonvignon J, Atherly DE, Peckenca C, Aikins M, Gazley L, Groman D, Narh CT, Armah G. Cost-effectiveness of rotavirus vaccination in Ghana: examining impacts from 2012 to 2031. Vaccine. 2017;35(24):3172–31. doi:10.1016/j.vaccine.2017.11.080.
severe rotavirus disease through the second year of life, Bolivia 2013-2014. Clin Infect Dis. 62:S115–20. doi:10.1093/cid/civ1026.

47. Gastanaduy PA, Contreras-Roldan I, Bernart C, Lopez B, Benoît SR, Xuya M, Muñoz F, Desai R, Quaye O, Tam KJ, et al. 2016. Effectiveness of monovalent and pentavalent rotavirus vaccines in Guatemala. Clin Infect Dis. 62:S121–26. doi:10.1093/cid/civ1208.

48. Groome MJ, Moyes J, Cortese M, Moyes J, Zarl HJ, Kapongo CN, Mulligan L, Diedericks R, Cohen C, Fleming JA, et al. 2014. Effectiveness of monovalent rotavirus vaccine against hospitalization for acute rotavirus diarrhoea in South African children: a case control study. Lancet Infect Dis. 14:1096–1104. doi:10.1016/S1473-3099(14)70940-5.

49. Groome MJ, Zell ER, Solomon F, Nzenze S, Parashar UD, Izu A, Madhi SA. 2016. Temporal association of rotavirus vaccine introduction and reduction in all cause childhood diarrheal hospitalizations in South Africa. Clin Infect Dis. 62:S188–95. doi:10.1093/cid/civ1204.

50. Sanchez-Urbez E, Esparaza-Aguilar M, Parashar UD, Richardson V. 2016. Sustained reduction in childhood diarrhoea mortality and hospitalizations in Mexico after rotavirus vaccine universalization. Clin Infect Dis. 62:S133–39. doi:10.1093/cid/civ1205.

51. Donato CM, Cowley D, Snelling TL, Akopov A, Kirkness EF, Kirkwood CD. 2014. Characterization of a G1P[8] rotavirus causing an outbreak of gastroenteritis in the Northern Territory, Australia, in the vaccine era. Emerg Microbes Infect. 3:e47. doi:10.1038/emr.2014.47.

52. Payne DC, Staat MA, Edwards KM, Szilagy PG, Weinberg GA, Hall CB, Chappell J, Curns AT, Wikswo M, Tate JE, et al. 2011. Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US Counties, 2006-2009. Clin Infect Dis. 53:245–253. doi:10.1093/cid/cir307.

53. Lopman BA, Curns AT, Yen C, Parashar UD. 2011. Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis. 204:980–986. doi:10.1093/infdis/jir492.

54. Anderson EJ, Shippée DB, Weinrobe MH, Davila MD, Katz BZ, Reddy S, Cuyugan MGKP, Lee SY, Simons YM, Yoge r et al. 2013. Indirect protection of adults from rotavirus by pediatric rotavirus vaccination. Clin Infect Dis. 56:755–760. doi:10.1093/cid/cis1010.

55. Buttery JP, Lambert SB, Grimwood K, Nissen MD, Field EJ, Macartney KK, Akikusa JD, Kelly JJ, Kirkwood CD. 2011. Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia’s National Childhood vaccination schedule. Pediatr Infect Dis J. 30:S25–9. doi:10.1097/INF.0b013e3181f1edee.

56. Paulke-Korinek M, Kundi M, Rendi-Wagner P, Kollaritsch H. 2011. Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria. Vaccine. 29:2791–2796. doi:10.1016/j.vaccine.2011.01.104.

57. Hanquet G, Ducroffre G, Vergison A, Neels P, Sabbe M, Van Damme P, Van Herck K. 2011. Impact of rotavirus vaccination on laboratory confirmed cases in Belgium. Vaccine. 29:4698–4703. doi:10.1016/j.vaccine.2011.04.098.

58. Msimang VM, Page NA, Groome MJ, Moyes J, Cortese MM, Seheri M, Kahn K, Chagan M, Madhi SA, Cohen C. 2013. Impact of rotavirus vaccine on childhood diarrheal hospitalization after introduction into the South African public immunization program. Pediatr Infect Dis J. 32:1359. doi:10.1097/INF.0b013e31827e6c60.

59. Zaman K, Sack DA, Neuzil KM, Page S, Saur K, Camps C, Kaisaki P, Gupta A, Talbot D, Middleton M, et al. 2017. Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: A cluster-randomized trial. PLoS Med. 14:e1002282. doi:10.1371/journal.pmed.1002230.
75. Gentsch JR, Laird AR, Bielfelt B, Griffin DD, Banyai K, Ramachandran M, Jain V, Cunliiffe NA, Nakagomi O, Kirkwood CD, et al. Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccination programs. J Infect Dis. 2005;192(Suppl 1):S146–59. doi:10.1086/431499.

76. Banyai K, Laszlo B, Voydani J, Steele AD, Nelson EAS, Gentsh JR, Parashar UD. 2012. Systematic Review of regional and temporal trends in global rotavirus strain diversity in the pre-rotavirus vaccine era: insights for understanding the impact of rotavirus vaccination programs. Vaccine. 30(S):A122–30. doi:10.1016/j.vaccine.2011.09.111.

77. Sanchez-Padilla E, Grais RF, Guerin PJ, Steele AD, Burny M-E, Luquero FJ. 2009. Burden of disease and circulating serotypes of rotavirus infection in Sub-Saharan Africa: systematic review and meta-analysis. Lancet Infect Dis. 9:567–576. doi:10.1016/S1473-3099(09)70179-3.

78. Miles M, Lewis K, Kang G, Parashar UD, Steele AD. 2012. A systematic review of rotavirus strain diversity in India, Bangladesh, and Pakistan. Vaccine. 30(S):A131–3. doi:10.1016/j.vaccine.2011.10.002.

79. Steele AD, Neuzil KM, Cunliiffe NA, Sansoathy N, Sichan K, Kaldor J, Evans JL, Maher L, Palefsky J. 2012. Human rotavirus vaccine Rotarix, provides protection against diverse circulating rotavirus strains in African infants. BMC Infect Dis. 12:213. doi:10.1186/1471-2334-12-166.

80. Correira JB, Patel M, Nakagomi O, Montenegro FMU, Germino EM, Correira NB, Cuevas LE, Parashar UD, Cunliiffe NA, Nakagomi T. 2010. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serologically-unrelated G2P[4] strains in Brazil. J Infect Dis. 201:363–369. doi:10.1086/649843.

81. Breiman RF, Zaman K, Armah GE, Sow SO, Anh DD, Victor JC, Hille D, Ciarlet M, Neuzil KM. 2012. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical trial of the oral pentavalent rotavirus vaccine. Vaccine. 30(S):A24–9. doi:10.1016/j.vaccine.2011.08.124.

82. Leshem E, Lopman B, Glass R, Moyes J, Zar HJ, Kapongo CN, Mulligan C, Diedericks R, Cohen C, Fleming JA, et al. 2014. Distribution of rotavirus strains and strain-specific effectiveness of the rotavirus vaccine after its introduction: a systematic review and meta-analysis. Lancet Infect Dis. 14:847–856. doi:10.1016/S1473-3099(14)70940-5.

83. Linhares AC, Justino MCA. 2014. Rotavirus vaccination in Brazil: effectiveness and health impact 7 years post-introduction. Exp Rev Vaccines. 13:43–57. doi:10.1080/14766858.2014.861746.

84. Kirkwood CD, Boniface K, Barnes GL, Bishop RF. 2011. Distribution of rotavirus genotypes after introduction of rotavirus vaccines, Rotarix® and RotaTeq®, into the national immunization programs. Vaccine. 29:1242–1247. doi:10.1016/j.vaccine.2010.11.087.

85. Appaiahgari MB, Glass R, Singh S, Taneja S, Rongsen-Chandola T, Bhandari N, Mishra S, Vrati S. 2014. Transplacental rotavirus IgG interferes with immune response to live oral rotavirus vaccine ORV-116E in Indian infants. Vaccine. 32:651–656. doi:10.1016/j.vaccine.2013.12.017.

86. Becker-Drepps S, Vilchez S, Velasquez D, Moon -S-S, Hudgens MG, Zambrana LE, Jiang B. 2015. Rotavirus-specific IgG antibodies from mothers’ serum may inhibit infant immune responses to the pentavalent rotavirus vaccine. Pediatr Infect Dis J. 34:115–116. doi:10.1098/arep.18585.

87. Moon SS, Groome MJ, Velasquez D, Parashar UD, Jones S, Koen A, van Niekerk N, Jiang B, Madhi SA. 2016. Pre-vaccination rotavirus serum IgG and IgA are associated with lower immunogenicity of live, oral human rotavirus vaccine in South African infants. Clin Infect Dis. 62:157–165. doi:10.1093/cid/civ828.

88. Kirkwood CD, Boniface K, Richardson S, Taraporewala ZF, Patton JT, Bishop RF. 2008. Non-structural protein NSP2 induces heterogeneous antibody responses during primary rotavirus infection and re-infection in children. J Med Virol. 80:1090. doi:10.1002/jmv.20971.

89. Vizzi E, Calvino E, Gonzalez R, Pérez-Schael I, Ciarlet M, Kang G, Estes MK, Liprandi F, Ludert JE. 2005. Evaluation of serum antibody responses against the rotavirus non-structural protein NSP4 in children after rhesus rotavirus tetravalent vaccination or natural infection. Clin Diag Lab Immunol. 12:1157–1163. doi:10.1128/CDDL.12.1157-1163.2005.

90. Holloway G, Coulson BS. 2013. Innate cellular responses to rotavirus infection. J Gen Virol. 94:1151–1160. doi:10.1099/vir.0.051276-0.

91. Conlon JD, Jeffery J, Black RE, Huisman TW, Mychaleckyj JC, Kirkpatrick B, Colgate R, Carmolli M, et al. 2015. Effect of withholding breastfeeding at the time of vaccination on the immunogenicity of oral rotavirus vaccine: A randomized trial. PLoS ONE. 10:e0127622. doi:10.1371/journal.pone.0127622.

92. Keusch GT, Denno DM, Black RE, Duggan C, Guerrant RL, Ritchie E, Keusch GT, Denno DM, Black RE, Duggan C, Guerrant RL. 2010. Environmental enteric dysfunction: pathogenesis, diagnosis and clinical consequences. Clin Infect Dis. 59:S207–212. doi:10.1093/cid/ciu485.

93. Naylor C, Lu M, Haque R, Mondal D, Buonomo E, Nayak U, Mychaleckyj JC, Kirkpatrick B, Colgate R, Carmolli M, et al. 2015. Environmental enteropathy, oral vaccine failure and growth faltering in infants in Bangladesh. EBioMedicine. 2:1759–1766. doi:10.1016/j.ebiom.2015.09.036.

94. Kirkwood CD, Boniface K, Richardson S, Taraporewala ZF, Patton JT, Bishop RF. 2008. Non-structural protein NSP2 induces heterogeneous antibody responses during primary rotavirus infection and re-infection in children. J Med Virol. 80:1090. doi:10.1002/jmv.20971.
103. Nordgren J, Nitiema LW, Ouermi D, Simpore J, Svensson L, Kapoor A. 2013. Host genetic factors affect susceptibility to norovirus infections in Burkina Faso. PLoS ONE. 8:e69557. doi:10.1371/journal.pone.0069557.

104. Nordgren J, Sharma S, Bucardo F, Nasir W, Günaydın G, Ouermi D, Nitiema LW, Becker-Drèps S, Simpore J, Hammarström L, et al. 2014. Both Lewis and Secretor status mediate susceptibility to rotavirus infections in a rotavirus genotype-dependent manner. Clin Infect Dis. 59:1567–1573. doi:10.1093/cid/ciu633.

105. Lee B, Dickson DM, deCamp AC, Ross Colgate E, Diehl SA, Uddin MI, Sharmi S, Islam S, Bhiuyan TR, Alam M, et al. Histoblood group antigen phenotype determines susceptibility to genotype-specific rotavirus infections and impacts measures of rotavirus vaccine efficacy. J Infect Dis. 2018 Jan 30;217:1399–1407. doi:10.1093/infdis/jiy054.

106. Harris VC, Armah GE, Fuentes S, Korpela KE, Parashar U, Victor JC, Tate J, de Weerth C, Giaquinto C, Wiersinga WJ, et al. 2017. Significant correlation between the infant gut microbiome and rotavirus vaccine response in rural Ghana. J Infect Dis. 215:34–41. doi:10.1093/infdis/jiw518.

107. Armah GE, Lewis K, Cortese M, Parashar UD, Ansah A, Gazley L, Victor JC, McNeal MM, Binka F, Steele AD. 2016. A randomized controlled trial of the impact of alternative dosing schedules on the immune response to human rotavirus vaccine in rural Ghanaian infants. J Infect Dis. 213:1678–1685. doi:10.1093/infdis/jiw023.

108. Harris V, Ali A, Fuentes S, Korpela K, Kazi M, Tate J, Parashar U, Wiersinga WJ, Giaquinto C, de Weerth C, et al. Rotavirus vaccine response correlates with the infant gut microbiota composition in Pakistan. Gut Microbes. 2018;9(2):93–101.

109. Parker EPK, Praharaj I, Zekavati A, Lazarus RP, Giri S, Operario DJ, Liu J, Houpt E, Iturriza-Gómez M, Kampmann B, et al. 2018. Influence of the intestinal microbiota on the immunogenicity of oral rotavirus vaccine given to infants in South India. Vaccine. 36:264–272. doi:10.1016/j.vaccine.2017.11.031.

110. Vesikari T, Karvonen A, Puustunen L, Zeng S-Q, Szakal ED, Delem A, De Vos B. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J. 2004;23:937–943.

111. Salinas R, Perez-Schael I, Linhares AC, Ruiz Palacios GM, Guerrero ML, Yarzabal JP, Cervantes Y, Clemens SC, Damaso S, Hardt K, et al. 2005. Evaluation of the safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J. 24:807–816. doi:10.1097/01.inf.0000178294.13954.a1.

112. Ali SA, Kazi AM, Cortese MM, Fleming JA, Parashar UD, Jiang B, McNeal MM, Steele D, Bhatta Z, Zaidi A. 2014. Impact of different dosing schedules on the immunogenicity of the human rotavirus vaccine in infants in Pakistan: a randomized trial. J Infect Dis. 210:1772–1779. doi:10.1093/infdis/jiu335.

113. Steele AD, Reynolds J, Scholtz F, Bos P, de Beer MC, Tumbo J, Van der Merwe CF, Delem A, De Vos B. 2010. Comparison of two different regimens (two doses versus three doses) in terms of reactogenicity and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 in South Africa infants. J Infect Dis. 202:593–100. doi:10.1086/653550.

114. Zaman K, Fleming JA, Victor JC, Yunus M, Bari TIA, Azim T, Rahman M, Mowla SMN, Bellini WJ, McNeal M, et al. 2016. Noninterference of rotavirus vaccine with measles-rubella vaccine at 9 months of age and improvements in anti-rotavirus immunity: a randomized trial. J Infect Dis. 213:1686–1693. doi:10.1093/infdis/jiw024.

115. Haidara FC, Tapia MD, Sow D, Doumbia M, Coulibaly F, Diallo F, Traoré A, Kadio M, Kelly CL, Fitzpatrick M, et al. Evaluation of a booster dose of pentavalent rotavirus vaccine co-administered with measles, yellow fever, and meningitis a vaccines in 9-month-old malian infants. J Infect Dis. 2018 Jul 13;218(4):606–613. doi:10.1093/infdis/jiy215.

116. Burnett E, Lopman BA, Parashar UD. 2017. Potential for a booster dose of rotavirus vaccine to further reduce diarrhea mortality. Vaccine. 35:7198–7203. doi:10.1016/j.vaccine.2017.10.027.

117. WHO. 2015. Maternal and neonatal tetanus elimination: validation survey in 4 States and 2 Union Territories in India, May 2015. Weekly Epidemiol Rec. 90:589–608.

118. Bines JE, Al Thobari J, Satria CD, Handley A, Watts E, Cowley D, Nirwati H, Ackland J, Standish J, Justice F, et al. 2018. Human Neonatal Rotavirus Vaccine (RV3-BB) to target rotavirus from birth. N Engl J Med. 378:719–730. doi:10.1056/NEJMoal1708804.

119. Vesikari T. 2015. Neonatal rotavirus vaccines making headway (Editorial). Lancet Infect Dis. 15:1362–1363. doi:10.1016/S1473-3099(15)00295-9.

120. Shankar AH, Prasad AS. 1998. Zinc and immune function: the biological basis of altered resistance to infection. Am J Clin Nutr. 68:447–463. doi:10.1093/ajcn/68.2.447S.

121. Albert MJ, Qadri F, Wahed MA, Ahmed T, Rahman ASMH, Ahmed F, Bhiuyan NA, Zaman K, Baqui AH, Clemens JD, et al. 2003. Supplementation with zinc, but not vitamin A, improves seroconversion to vibriocidal antibody in children given an oral cholera vaccine. J Infect Dis. 187:909–913. doi:10.1086/368132.

122. Ahmed T, Svensnerholm AM, Al Tarique A, Sultana GNN, Qadri F. 2009. Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding. Vaccine. 27:1433–1439. doi:10.1016/j.vaccine.2008.12.036.

123. Round JL, Mazmanian SK. 2009. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 9:313–323. doi:10.1038/nri2515.

124. Kandasamy S, Chatttha KS, Vlasova AN, Rajashekar G, Saif LJ. 2014. Lactobacilli and Bifidobacteria enhance mucosal B cell responses and differentially modulate systemic antibody responses to an oral human rotavirus vaccine in a neonatal gnotobiotic pig disease model. Gut Microbes. 5:639–651. doi:10.4161/21504130.2014.949972.

125. Mao X, Gu C, Hu H, Tang J, Chen D, Yu B, He J, Yu J, Luo J, Tian G, et al. 2016. Dietary Lactobacillus rhamnosus GG supplementation improves the mucosal barrier function in the intestine of weaned piglets challenged by porcine rotavirus. PLoS ONE. 11: e0146312. doi:10.1371/journal.pone.0146312.

126. Lazarus RP, John J, Shanmugasundaram E, Rajan AK, Thiijarajan S, Giri S, Babji S, Sarkar R, Kaliappan PS, Venugopal S, et al. 2018. A randomized double blind placebo-controlled trial of supplementation with Zinc and/or probiotics to enhance the immune response of oral rotavirus and polio vaccines in Indian infants. Vaccine. 36:273–295. doi:10.1016/j.vaccine.2017.07.116.

127. Gavi. Rotavirus roadmap public summary. The market shaping goal. Supply Procure Roadmap – Rotavirus. 2013 Oct 31. www.gavialliance.org/.
